Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 7/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 7/20 | 0.51 |
| ▸ | VKORC1 | Q9BQB6 | 3/20 | 0.51 |
| ▸ | TOP2A | P11388 | 1/20 | 0.49 |
| ▸ | TOP1 | P11387 | 1/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tioclomarol SCHEMBL13724182 | 0.88 | THRB (0.47) | NQO1THRBCYP2C9VKORC1TOP2A | |
| SCHEMBL1651856 | 0.87 | THRB (0.42) | NQO1THRBCYP2C9VKORC1TOP2A | |
| SCHEMBL7406235 | 0.76 | CYP2C9 (0.82) | NQO1CYP2C9VKORC1TOP1CRHBP | |
| SCHEMBL12028898 | 0.75 | NQO1 (1.00) | NQO1CYP2C9TOP2ATOP1CRHBP | |
| SCHEMBL1649084 | 0.74 | NQO1 (0.70) | NQO1CYP2C9VKORC1TOP2ATOP1 | |
| Coumachlor SCHEMBL30930052 | 0.73 | CYP2C9 (0.84) | NQO1CYP2C9VKORC1CRHBPCASP7 | |
| Coumachlor SCHEMBL433455 | 0.73 | CYP2C9 (0.84) | NQO1CYP2C9VKORC1CRHBPCASP7 | |
| SCHEMBL18962174 | 0.72 | THRB (0.80) | NQO1THRBCYP2C9VKORC1TOP1 | |
| Bromodiolone SCHEMBL29362860 | 0.72 | THRB (1.00) | NQO1THRBCYP2C9VKORC1TOP2A | |
| Bromodiolone SCHEMBL433993 | 0.72 | THRB (1.00) | NQO1THRBCYP2C9VKORC1TOP2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1730 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938040-B1 | VITAMIN K2 IN COMBINATION WITH ANTICOAGULANTS FOR USE IN TREATING MUSCLE SORENESS | LESAFFRE & CIE (FR) | 2025-05-21 | — | — | EP | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240034752-A1 | ARTIFICIAL SHORT INTERFERING PEPTIDE FOR THE PHOSPHORYLATION SUBSTRATE OF DAPK1 AND ITS PHARMACEUTICAL APPLICATIONS | BEIJING SINANCHENG TECHNOLOGY CO., LTD. (CN) | 2024-02-01 | — | — | US | claimed |
| EP-4293037-A1 | ARTIFICIAL SMALL MOLECULE INTERFERING PEPTIDE OF DAPK1 PHOSPHORYLATED SUBSTRATE AND PHARMACEUTICAL USE THEREOF | Beijing Sinancheng Technology co., Ltd. (CN) | 2023-12-20 | — | — | EP | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| US-11421234-B2 | Aptamers for targeting coagulation factor XIII and uses thereof | CHANG GUNG UNIVERSITY (TW) | 2022-08-23 | — | — | US | claimed |
| EP-3964208-A1 | COMPOSITION COMPRISING ISOQUERCETIN FOR TREATING VENOUS THROMBOSIS | Quercegen Pharmaceuticals LLC (US) | 2022-03-09 | — | — | EP | claimed |
| US-20210371512-A1 | Use of IL-1 beta Binding Antibodies | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | claimed |
| EP-1343506-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO 4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GmbH (DE) | 2003-09-17 | — | — | EP | claimed |
| EP-1309354-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | Rutgers, The State University (US) | 2003-05-14 | — | — | EP | claimed |
| US-20020173818-A1 | Delivering an agent to a patient's body | BOSTON SCIENTIFIC SCIMED, INC. | 2002-11-21 | — | — | US | claimed |
| WO-2002091957-A1 | DELIVERING AN AGENT TO A PATIENT'S BODY | SCIMED LIFE SYSTEM, INC. (US) | 2002-11-21 | — | — | WO | claimed |
| WO-2002062322-A2 | GLYCINE BETAINE AND ITS USE AS ANTI-HEMORRHAGIC AGENT | MESSADEK JALLAL (BE) | 2002-08-15 | — | — | WO | claimed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049650-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| WO-2002049651-A1 | PHARMACEUTICAL FORMULATION CONTAINING PYRAZOLO[4,3-D]PYRIMIDINES AND ANTITHROMBOTIC AGENTS, CALCIUM-ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | claimed |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | POLYMERIX CORPORATION | 2002-06-13 | — | — | US | claimed |
| WO-2002009768-A2 | THERAPEUTIC POLYESTERS AND POLYAMIDES | RUTGERS, THE STATE UNIVERSITY (US) | 2002-02-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | NQO1 234/4885THRB 3137/4885CYP2C9 4501/4885 |
| US-20020071822-A1 | Therapeutic polyesters and polyamides | NPEPPS, PAICS, PUF60 | NQO1 3920/4885THRB 3388/4885CYP2C9 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.